Therapeutic Area: Oncology

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation

Pagliuca S, et al.
Nature Communications
August 2023
Authors and Affiliates
Simona Pagliuca 1,2,3, Carmelo Gurnari 1,4, Colin Hercus 5, Sébastien Hergalant 6, Sanghee Hong 7, Adele Dhuyser 3,8, Maud D'Aveni 2,3, Alice Aarnink 3,8, Marie Thérèse Rubio 2,3, Pierre Feugier 2, Francesca Ferraro 9, Hetty E Carraway 10, Ronald Sobecks 11, Betty K Hamilton 11, Navneet S Majhail 12, Valeria Visconte 1, Jaroslaw P Maciejewski 13; 1 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 2 Department of Hematology, CHRU de Nancy, Vandœuvre-lès-Nancy, France. 3 CNRS UMR 7365, IMoPA, Biopole of University of Lorraine, Vandœuvre-lès-Nancy, France. 4 Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy. 5 Novocraft Technologies Sdn Bhd, Kuala Lumpur, Malaysia. 6 Inserm UMR-S 1256 Nutrition-Genetics-Environmental Risk Exposure, University of Lorraine, 54500, Vandœuvre-lès-Nancy, France. 7 Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. 8 Histocompatibility Department, CHRU de Nancy, Vandœuvre-lès-Nancy, France. 9 Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA. 10 Leukemia Program, Hematology Department, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 11 Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. 12 Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN, USA. 13 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.

Izutsu K, et al.
International Journal of Hematology
August 2023
Authors and Affiliates
Koji Izutsu1  Kazuhito Yamamoto2 Koji Kato3 Takayuki Ishikawa4 Noriko Fukuhara5 Yasuhito Terui6,7 Ilseung Choi8· Sumiko Okubo9 Natsumi Ogawa10 Mizu Sakai10 Yasuko Nishimura10 Brenda Chyla11 Yan Sun11 Dai Maruyama1,6 1 Department of Hematology, National Cancer Center Hospital, Tokyo, Japan2 Department of Hematology and Cell Therapy, Aichi Cancer Center, Aichi, Japan3 Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan4 Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan5 Department of Hematology, Tohoku University Hospital, Miyagi, Japan6 Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan7 Department of Hematology, Saitama Medical University Hospital, Saitama, Japan8 Department of Hematology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan9 AbbVie GK, Osaka, Japan10 AbbVie GK, Tokyo, Japan11 AbbVie, Inc, North Chicago, IL, USA

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.

Siddiqi T, et al.
The Lancet
June 2023
Authors and Affiliates
Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N Shah, Rajneesh Nath, Bita Fakhri, Deborah M Stephens, Shuo Ma, Tatyana Feldman, Scott R Solomon, Stephen J Schuster, Serena K Perna, Sherilyn A Tuazon, San-San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G Wierda Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA (T Siddiqi MD);Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA (Prof D G Maloney MD); Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA(S S Kenderian MBChB); Division of Hematologic Malignancies & Cellular Therapy, Duke University Health System, Durham, NC, USA(D M Brander MD); Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA(K Dorritie MD); Department of Medicine, Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA(J Soumerai MD); Section of Hematology/Oncology, Department of Medicine, The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA(P A Riedell MD); Cancer Center, Froedtert Hospital, Medical College of Wisconsin, Milwaukee, WI, USA(N N Shah MD); Stem Cell Transplantation Cellular Therapy and Acute Leukemia, Banner MD Anderson Cancer Center, Gilbert, AZ, USA(R Nath MD); Department of Medicine, Division of Hematology and Blood and Marrow Transplant, University of California San Francisco, San Francisco, CA, USA(B Fakhri MD); Internal Medicine and Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA(D M Stephens DO); Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA(Prof S Ma MD); T Cell Lymphoma Program, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA (T Feldman MD); Transplant and Cellular Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA, USA (S R Solomon MD);Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA(Prof S J Schuster MD); Bristol Myers Squibb, Princeton, NJ, USA (S K Perna MD, Y Chen PhD);Bristol Myers Squibb, Seattle, WA, USA (S A Tuazon MD, S-S Ou MS, E Papp PhD, L Peiser DPhil); Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA(Prof W G Wierda MD)

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

Hill JA, et al.
May 2023
Authors and Affiliates
Joshua A Hill 1 2, Michael J Martens 3 4, Jo-Anne H Young 5, Kavita Bhavsar 3, Jianqun Kou 3, Min Chen 3, Lik Wee Lee 6, Aliyah Baluch 7, Madhav V Dhodapkar 8, Ryotaro Nakamura 9, Kristin Peyton 10, Zainab Shahid 11, Paul Armistead 12, Peter Westervelt 13, John McCarty 14, Joseph McGuirk 15, Mehdi Hamadani 16, Susan DeWolf 11, Kinga Hosszu 11, Elad Sharon 17, Ashley Spahn 18, Amir A Toor 14, Stephanie Waldvogel 18, Lee M Greenberger 19, Jeffery J Auletta 18 20, Mary M Horowitz 3, Marcie L Riches 3, Miguel-Angel Perales 11 21; 1 Vaccine and Infectious Disease, Fred Hutchinson Cancer Center, Seattle, WA, USA. 2 Department of Medicine, University of Washington, Seattle, WA, USA. 3 Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, WI, USA. 4 Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA. 5 University of Minnesota, Minneapolis, MN, USA. 6 Adaptive Biotechnologies Corp, Seattle, WA, USA. 7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 8 Emory University - School of Medicine, Atlanta, GA, USA. 9 City of Hope, Duarte, CA, USA. 10 The Emmes Company, Rockville, MD, USA. 11 Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 University of North Carolina Medical Center, Chapel Hill, NC, USA. 13 Barnes-Jewish Hospital, Washington University, St. Louis, MO, USA. 14 Virginia Commonwealth University, Richmond, VA, USA. 15 University of Kansas, Lawrence, KS, USA. 16 Medical College of Wisconsin, Milwaukee, WI, USA. 17 National Cancer Institute, Bethesda, MD, USA. 18 National Marrow Donor Program/Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA. 19 The Leukemia and Lymphoma Society, Rye Brook, New York, NY, USA. 20 Nationwide Children's Hospital, Columbus, OH, USA. 21 Weil Cornell Medical College, New York, NY, USA.

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas LA, et al.
May 2023
Authors and Affiliates
Luis A. Rojas #1,2, Zachary Sethna #1,2, Kevin C. Soares 2,3, Cristina Olcese 2, Nan Pang 2, Erin Patterson 2, Jayon Lihm 4, Nicholas Ceglia 4, Pablo Guasp 1,2, Alexander Chu 4, Rebecca Yu 1,2, Adrienne Kaya Chandra 1,2, Theresa Waters 1,2, Jennifer Ruan 1,2, Masataka Amisaki 1,2, Abderezak Zebboudj 1,2, Zagaa Odgerel 1,2, George Payne 1,2, Evelyna Derhovanessian 5, Felicitas Müller 5, Ina Rhee 6, Mahesh Yadav 6, Anton Dobrin 7,8, Michel Sadelain 7,8, Marta Łuksza 9, Noah Cohen 10, Laura Tang 11, Olca Basturk 11, Mithat Gönen 12, Seth Katz 13, Richard Kinh Do13, Andrew S. Epstein 14, Parisa Momtaz 14, Wungki Park 3,14, Ryan Sugarman 14, Anna M. Varghese 14, Elizabeth Won 14, Avni Desai 14, Alice C. Wei 2,3, Michael I. D’Angelica 2,3, T. Peter Kingham 2,3, Ira Mellman 6, Taha Merghoub 15, Jedd D. Wolchok 15, Ugur Sahin 5, Özlem Türeci 5,16, Benjamin D. Greenbaum (corresponding author) 4,17, William R. Jarnagin 2,3, Jeffrey Drebin 2,3, Eileen M. O’Reilly 3,14, and Vinod P. Balachandran (corresponding author) 1,2,3; 1 Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY USA. 2 Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY USA. 3 David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY USA. 4 Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY USA. 5 BioNTech, Mainz, Germany. 6 Genentech, San Francisco, CA USA. 7 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY USA. 8 Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY USA. 9 Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA. 10 Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY USA. 11 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY USA. 12 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY USA. 13 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY USA. 14 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY USA. 15 Meyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY USA. 16 HI-TRON, Helmholtz Institute for Translational Oncology, Mainz, Germany. 17 Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY USA.

TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs

Genolet R, et al.
May 2023
Authors and Affiliates
Raphael Genolet 1,2,4,∗ Sara Bobisse 1,2, Johanna Chiffelle 1,2, Marion Arnaud 1,2, Rémy Petremand 1,2, Lise Queiroz 1,2, Alexandra Michel 1,2, Patrick Reichenbach 1, Julien Cesbron 1,2 Aymeric Auger 1,2, Petra Baumgaertner 1,2, Philippe Guillaume 1,2, Julien Schmidt 1,2, Melita Irving 1, Lana E. Kandalaft1,2, Daniel E. Speiser 1, George Coukos 1,3,∗∗ and Alexandre Harari 1,3,∗∗∗; 1 Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland. 2 Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland. Raphael Genolet: hc.vuhc@teloneg.leahpar; George Coukos: hc.vuhc@sokuoc.egroeg; Alexandre Harari: hc.vuhc@irarah.erdnaxela

Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies.

Patel DA, et al.
April 2023
Authors and Affiliates
Dilan A. Patel, Fei Wan, Kathryn Trinkaus, Daniel G. Guy, Natasha Edwin, Marcus Watkins, Nancy L. Bartlett, Amanda Cashen, Todd A. Fehniger, Armin Ghobadi, Neha-Mehta Shah, Brad S. Kahl Washington University in St Louis School of Medicine, St Louis, MO, 63110

Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

Pai JA, et al.
April 2023
immuneAccess
Authors and Affiliates
Joy A Pai 1, Matthew D Hellmann 2, Jennifer L Sauter 3, Marissa Mattar 4, Hira Rizvi 5, Hyung Jun Woo 6, Nisargbhai Shah 7, Evelyn M Nguyen 8, Fathema Z Uddin 7, Alvaro Quintanal-Villalonga 7, Joseph M Chan 7, Parvathy Manoj 7, Viola Allaj 7, Marina K Baine 3, Umesh K Bhanot 9, Mala Jain 9, Irina Linkov 9, Fanli Meng 6, David Brown 6, Jamie E Chaft 10, Andrew J Plodkowski 11, Mathieu Gigoux 12, Helen H Won 6, Triparna Sen 10, Daniel K Wells 13, Mark T A Donoghue 6, Elisa de Stanchina 4, Jedd D Wolchok 14, Brian Loomis 6, Taha Merghoub 14, Charles M Rudin 15, Andrew Chow 16, Ansuman T Satpathy 17; 1 Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Program, Stanford University, Stanford, CA, USA. 2 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3 Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4 Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5 Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6 Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Cancer Biology Program, Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9 Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 11 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 12 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 13 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Santa Ana Bio, Alameda, CA, USA. 14 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 16 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: chowa1@mskcc.org. 17 Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Program, Stanford University, Stanford, CA, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, Stanford University, Stanford, CA, USA. Electronic address: satpathy@stanford.edu.

Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders

John J, et al.
April 2023
immuneAccess
Authors and Affiliates
Jessy John 1, Samantha M Y Chen 2, Rachel A Woolaver 2, Huaibin Ge 1, Monika Vashisht 1, Ziyu Huang 3, Zhangguo Chen 1, Jing H Wang 1,4; 1 UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States. 2 Department of Immunology and Microbiology, University of Colorado, School of Medicine, Aurora, CO, United States. 3 UPMC Hillman Cancer Center Biostatistics Facility, University of Pittsburgh, Pittsburgh, PA, United States. 4 Department of Immunology, University of Pittsburgh, Pittsburgh, PA, United States.

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

Shenderov E, et al.
April 2023
immuneAccess
Authors and Affiliates
Eugene Shenderov 1,2, Angelo M De Marzo 3,4,5, Tamara L Lotan 3,4,5, Hao Wang 6, Sin Chan 3, Su Jin Lim 6, Hongkai Ji 7, Mohamad E Allaf 5, Carolyn Chapman 3, Paul A Moore 8, Francine Chen 8, Kristina Sorg 9, Andrew M White 9, Sarah E Church 9, Briana Hudson 9, Paul A Fields 10, Shaohui Hu 11, Samuel R Denmeade 3, Kenneth J Pienta 3, Christian P Pavlovich 5, Ashley E Ross 12, Charles G Drake 13, Drew M Pardoll 3,14, Emmanuel S Antonarakis 3,14,15; 1 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu. 2 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu. 3 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4 Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5 Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 6 Department of Oncology Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, MD, USA. 7 Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 8 MacroGenics, Inc., Rockville, MD, USA. 9 NanoString Technologies Inc., Seattle, WA, USA. 10 Adaptive Biotechnologies, Seattle, WA, USA. 11 CDI Labs, Baltimore, MD, USA. 12 Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 13 Immuno-Oncology, Janssen, Horsham, PA, USA. 14 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. 15 University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.